Psoriasis comorbidities: Results from the national psoriasis foundation surveys 2003 to 2011

April W. Armstrong, Clayton Schupp, Bruce Bebo

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

Background: Studies examining comorbidities among psoriasis patients with varying disease severities measured by body surface area (BSA) are lacking. Objective: To examine the association between psoriasis severity and comorbid conditions, including rheumatologic, cardiovascular and other immune-mediated diseases. Methods: From 2003 to 2011, the National Psoriasis Foundation conducted surveys among 5,604 psoriasis patients. The combined surveys represented the largest study to date that used BSA as a direct measure of psoriasis severity for comorbidity assessment. Results: Over 86% of psoriatic arthritis (PsA) patients reported presenting with psoriasis prior to PsA; the diagnosis of psoriasis preceded that of PsA by a mean period of 14.6 years. Compared to those with mild psoriasis, patients with moderate-to-severe psoriasis had significantly increased adjusted odds of PsA (moderate: odds ratio, OR: 1.21, 95% confidence interval, CI: 1.04-1.41; severe: OR: 2.32, 95% CI: 1.98-2.70). Patients with severe psoriasis had increased adjusted odds of diabetes (OR: 1.5, 95% CI: 1.08-2.08) and cardiovascular disease (OR: 1.5, 95% CI: 1.01-2.24) compared to those with mild-to-moderate psoriasis. Odds of rheumatoid arthritis, ankylosing spondylitis, lupus, Crohn's disease and multiple sclerosis were not significantly increased in patients with severe psoriasis. Conclusion: Compared to those with mild-to-moderate psoriasis, patients with severe psoriasis are at increased odds of PsA, diabetes and cardiovascular diseases.

Original languageEnglish (US)
Pages (from-to)121-126
Number of pages6
JournalDermatology
Volume225
Issue number2
DOIs
StatePublished - Nov 2012

Fingerprint

Psoriasis
Comorbidity
Psoriatic Arthritis
Body Surface Area
Surveys and Questionnaires
Cardiovascular Diseases
Ankylosing Spondylitis
Immune System Diseases
Crohn Disease
Multiple Sclerosis
Rheumatoid Arthritis
Odds Ratio
Confidence Intervals

Keywords

  • Cardiovascular disease
  • Comorbidities
  • Immune-mediated comorbidities
  • Psoriasis
  • Psoriatic arthritis

ASJC Scopus subject areas

  • Dermatology

Cite this

Psoriasis comorbidities : Results from the national psoriasis foundation surveys 2003 to 2011. / Armstrong, April W.; Schupp, Clayton; Bebo, Bruce.

In: Dermatology, Vol. 225, No. 2, 11.2012, p. 121-126.

Research output: Contribution to journalArticle

Armstrong, April W. ; Schupp, Clayton ; Bebo, Bruce. / Psoriasis comorbidities : Results from the national psoriasis foundation surveys 2003 to 2011. In: Dermatology. 2012 ; Vol. 225, No. 2. pp. 121-126.
@article{3cefaae3a0c2407eb73ed166d114bf5d,
title = "Psoriasis comorbidities: Results from the national psoriasis foundation surveys 2003 to 2011",
abstract = "Background: Studies examining comorbidities among psoriasis patients with varying disease severities measured by body surface area (BSA) are lacking. Objective: To examine the association between psoriasis severity and comorbid conditions, including rheumatologic, cardiovascular and other immune-mediated diseases. Methods: From 2003 to 2011, the National Psoriasis Foundation conducted surveys among 5,604 psoriasis patients. The combined surveys represented the largest study to date that used BSA as a direct measure of psoriasis severity for comorbidity assessment. Results: Over 86{\%} of psoriatic arthritis (PsA) patients reported presenting with psoriasis prior to PsA; the diagnosis of psoriasis preceded that of PsA by a mean period of 14.6 years. Compared to those with mild psoriasis, patients with moderate-to-severe psoriasis had significantly increased adjusted odds of PsA (moderate: odds ratio, OR: 1.21, 95{\%} confidence interval, CI: 1.04-1.41; severe: OR: 2.32, 95{\%} CI: 1.98-2.70). Patients with severe psoriasis had increased adjusted odds of diabetes (OR: 1.5, 95{\%} CI: 1.08-2.08) and cardiovascular disease (OR: 1.5, 95{\%} CI: 1.01-2.24) compared to those with mild-to-moderate psoriasis. Odds of rheumatoid arthritis, ankylosing spondylitis, lupus, Crohn's disease and multiple sclerosis were not significantly increased in patients with severe psoriasis. Conclusion: Compared to those with mild-to-moderate psoriasis, patients with severe psoriasis are at increased odds of PsA, diabetes and cardiovascular diseases.",
keywords = "Cardiovascular disease, Comorbidities, Immune-mediated comorbidities, Psoriasis, Psoriatic arthritis",
author = "Armstrong, {April W.} and Clayton Schupp and Bruce Bebo",
year = "2012",
month = "11",
doi = "10.1159/000342180",
language = "English (US)",
volume = "225",
pages = "121--126",
journal = "Dermatology",
issn = "1018-8665",
publisher = "S. Karger AG",
number = "2",

}

TY - JOUR

T1 - Psoriasis comorbidities

T2 - Results from the national psoriasis foundation surveys 2003 to 2011

AU - Armstrong, April W.

AU - Schupp, Clayton

AU - Bebo, Bruce

PY - 2012/11

Y1 - 2012/11

N2 - Background: Studies examining comorbidities among psoriasis patients with varying disease severities measured by body surface area (BSA) are lacking. Objective: To examine the association between psoriasis severity and comorbid conditions, including rheumatologic, cardiovascular and other immune-mediated diseases. Methods: From 2003 to 2011, the National Psoriasis Foundation conducted surveys among 5,604 psoriasis patients. The combined surveys represented the largest study to date that used BSA as a direct measure of psoriasis severity for comorbidity assessment. Results: Over 86% of psoriatic arthritis (PsA) patients reported presenting with psoriasis prior to PsA; the diagnosis of psoriasis preceded that of PsA by a mean period of 14.6 years. Compared to those with mild psoriasis, patients with moderate-to-severe psoriasis had significantly increased adjusted odds of PsA (moderate: odds ratio, OR: 1.21, 95% confidence interval, CI: 1.04-1.41; severe: OR: 2.32, 95% CI: 1.98-2.70). Patients with severe psoriasis had increased adjusted odds of diabetes (OR: 1.5, 95% CI: 1.08-2.08) and cardiovascular disease (OR: 1.5, 95% CI: 1.01-2.24) compared to those with mild-to-moderate psoriasis. Odds of rheumatoid arthritis, ankylosing spondylitis, lupus, Crohn's disease and multiple sclerosis were not significantly increased in patients with severe psoriasis. Conclusion: Compared to those with mild-to-moderate psoriasis, patients with severe psoriasis are at increased odds of PsA, diabetes and cardiovascular diseases.

AB - Background: Studies examining comorbidities among psoriasis patients with varying disease severities measured by body surface area (BSA) are lacking. Objective: To examine the association between psoriasis severity and comorbid conditions, including rheumatologic, cardiovascular and other immune-mediated diseases. Methods: From 2003 to 2011, the National Psoriasis Foundation conducted surveys among 5,604 psoriasis patients. The combined surveys represented the largest study to date that used BSA as a direct measure of psoriasis severity for comorbidity assessment. Results: Over 86% of psoriatic arthritis (PsA) patients reported presenting with psoriasis prior to PsA; the diagnosis of psoriasis preceded that of PsA by a mean period of 14.6 years. Compared to those with mild psoriasis, patients with moderate-to-severe psoriasis had significantly increased adjusted odds of PsA (moderate: odds ratio, OR: 1.21, 95% confidence interval, CI: 1.04-1.41; severe: OR: 2.32, 95% CI: 1.98-2.70). Patients with severe psoriasis had increased adjusted odds of diabetes (OR: 1.5, 95% CI: 1.08-2.08) and cardiovascular disease (OR: 1.5, 95% CI: 1.01-2.24) compared to those with mild-to-moderate psoriasis. Odds of rheumatoid arthritis, ankylosing spondylitis, lupus, Crohn's disease and multiple sclerosis were not significantly increased in patients with severe psoriasis. Conclusion: Compared to those with mild-to-moderate psoriasis, patients with severe psoriasis are at increased odds of PsA, diabetes and cardiovascular diseases.

KW - Cardiovascular disease

KW - Comorbidities

KW - Immune-mediated comorbidities

KW - Psoriasis

KW - Psoriatic arthritis

UR - http://www.scopus.com/inward/record.url?scp=84870795212&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870795212&partnerID=8YFLogxK

U2 - 10.1159/000342180

DO - 10.1159/000342180

M3 - Article

C2 - 23108113

AN - SCOPUS:84870795212

VL - 225

SP - 121

EP - 126

JO - Dermatology

JF - Dermatology

SN - 1018-8665

IS - 2

ER -